Impact of orphan drugs on Latvian budget

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Logviss, Konstantins ^a   Krievins, Dainis ^b,c   Purvina, Santa ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Budget impact; Expenditure; Latvia; Orphan drugs; Reimbursement

Indexed keywords

AMBRISENTAN; ANTINEOPLASTIC AGENT; BOSENTAN; DASATINIB; IDURONATE 2 SULFATASE; IMATINIB; NILOTINIB; ORPHAN DRUG; SILDENAFIL;

ARTICLE; BUDGET; CARDIOVASCULAR DISEASE; CHRONIC EOSINOPHILIC LEUKAEMIA; CHRONIC MYELOID LEUKEMIA; DERMATOFIBROSARCOMA PROTUBERANS; DRUG COST; ENDOCRINE DISEASE; ENZYME REPLACEMENT; EOSINOPHILIC LEUKEMIA; EUROPE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUNTER SYNDROME; HYPEREOSINOPHILIC SYNDROME; LATVIA; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; PATENT; PULMONARY HYPERTENSION; REIMBURSEMENT; RESPIRATORY TRACT DISEASE; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; MUCOPOLYSACCHARIDOSIS II; STATISTICS AND NUMERICAL DATA;

BUDGETS; COST-BENEFIT ANALYSIS; ENZYME REPLACEMENT THERAPY; HUMANS; LATVIA; MUCOPOLYSACCHARIDOSIS II; ORPHAN DRUG PRODUCTION;

EID: 84977612746     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0434-y     Document Type: Article

References (31)

1. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Offic J Europ Communities 2000, L18:1-5. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. Accessed 08.12.2015.
2. Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13/14):660-4.
3. Orofino J, Soto J, Casado MA, Oyaguez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010;8(5):301-15.
4. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173-9.
5. Iskrov G, Stefanov R: A comprehensive analysis of access to orphan drugs in Bulgaria, budget impact of medicinal therapies for rare diseases and good practices for rare disease patient access to orphan drugs in the EU. Centre for Analyses and Health Technology Assessment. Institute for Rare Diseases 2014
6. List of rare disease (orphan) designations. European Medicines Agency. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan-search.jsp&mid=WC0b01ac058001d12b. Accessed 08.12.2015.
7. European Community register of designated orphan medicinal products. European Commission. Available from http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm. Accessed 08.12.2015.
8. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36-42.
9. de Varax A, Letellier M, Börtlein G: Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe. Alcimed, Paris: 2004. Available from http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final-final-report-part-1-web-en.pdf. Accessed 08.12.2015.
10. Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ: Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open 2015, 5:e007199. Including web appendix 3. Available from http://bmjopen.bmj.com/content/suppl/2015/06/24/bmjopen-2014-007199.DC1. Accessed 08.12.2015.
11. Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275-9.
12. Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis. 2014;9:154.
13. Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis. 2014;9:22.
14. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011;6:62.
15. Schlander M, Adarkwah CC, Gandjour A. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):171-9.
16. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295-301.
17. Denis A, Simoens S, Fostier C, Mergaert L, Cleemput I: Policies for orphan diseases and orphan drugs. Health Technology Assessment (HTA). Belgian Health Care Knowledge Centre (KCE) 2009. KCE reports 112C (D/2009/10.273/32). Available from http://ec.europa.eu/health/ph-threats/non-com/docs/policies-orphan-en.pdf. Accessed 08.12.2015.
18. Pavlović N, Stanimirov B, Stojančević M, Paut-Kusturica M, Stoimenova A, Goločorbin-Kon S, Mikov M. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotec Eq. 2012;26(5):3236-41.
19. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy. 2012;108:10-8.
20. Logviss K, Krievins D, Purvina S. Rare diseases and orphan drugs: Latvian story. Orphanet J Rare Dis. 2014;9:147.
21. Order of reimbursement of medicines and medical devices for outpatient treatment. Regulation No. 899 of the Cabinet of Ministers (in Latvian). Riga 2006. Version of 01.06.2015. Available from http://likumi.lv/doc.php?id=147522. Accessed 08.12.2015.
22. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S. Market uptake of orphan drugs - a European analysis. J Clin Pharm Ther. 2012;37:664-7.
23. Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoens S. Critical assessment of Belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics. 2011;29(10):883-93.
24. Decision No. 995 of the Centre for Health Economics (in Latvian). Available from http://likumi.lv/doc.php?id=204266&version-date=28.01.2010. Accessed 02.03.2016.
25. Decision No. 686 of the Centre for Health Economics (in Latvian). Available from http://likumi.lv/doc.php?id=225007. Accessed 02.03.2016.
26. Data on total population. The World Bank. Available from http://data.worldbank.org/indicator/SP.POP.TOTL. Accessed 02.03.2016.
27. th Eurordis round table of companies workshop. 2007
28. Kesselman I, Elstein D, Israeli A, Chertkoff R, Zimran A. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Blood Cells Mol Dis. 2006;37(1):46-9.
29. Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet J Rare Dis. 2013;8:124.
30. Ylä-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol Ther. 2015;23(2):217-8.
31. Data on GDP per capita (PPP). The World Bank. Available from http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD. Accessed 02.03.2016.